Dr Lal PathLabs Q2 results: Profit jumps 54.8%, revenue rises 12.63%

Dr Lal PathLab's share price rose to 3.30 per cent, ending the day's trade at Rs 2,455 apiece on the BSE

Q2
On a sequential basis, the company exhibited an 11.1 per cent increase in revenue and the PAT increased at 32.4 per cent | Illustration: Ajay Mohanty
Anjali Singh Mumbai
2 min read Last Updated : Nov 02 2023 | 4:11 PM IST
Diagnostic and healthcare service provider Dr Lal PathLabs posted a 54.8 per cent year-on-year (Y-o-Y) increase in profit after tax (PAT) during the quarter concluded on September 30, 2023, reaching Rs 109.3 crore. The company also reported a 12.63 per cent increase in its consolidated revenue from operations, which came in at Rs 601.3 crore, in contrast to Rs 533.8 crore in the second quarter of financial year 24. This increase in PAT can be attributed to the reduction in financial costs and their expansion programmes.

On a sequential basis, the company exhibited an 11.1 per cent increase in revenue and the PAT increased at 32.4 per cent.

Commenting on the result, Om Manchanda, Managing Director stated: “We are seeing healthy and steady rise in DLPL’s revenue growth trends both in value and volume terms. The quarter also saw some rationality returning, where brands have taken measured price increases in their test portfolios. From focus on Tier-III and IV towns in strong markets of North and East to emphasising upon specialty and super-specialist portfolio; we have meticulously pursued growth drivers in this endeavour.”

Commenting on the performance, Bharath Uppiliappan, Chief Executive Officer said: “Our patient growth is significantly higher than our first quarter of FY 24 numbers; we served 7.5 million patients in the second quarter of FY 24 and 14.4 million patients in the first half of FY 24. Our expansion programme in Tier-III+ towns continues to show encouraging results. On the back of this response, we are planning to accelerate this journey by opening more new labs in Tier-III+ towns.”

Dr Lal PathLab's share price rose to 3.30 per cent, ending the day's trade at Rs 2,455 apiece on the BSE.

Dr Lal PathLabs is a provider of diagnostic and healthcare testing services in India. The company boasts a network of 277 clinical laboratories, 5,102 Patient Service Centres and 10,938 Pick-up Points.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Dr Lal PathLabsQ2 resultsHealthcare sector

First Published: Nov 02 2023 | 4:10 PM IST

Next Story